CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

Study Overview
=================
Brief Summary
-----------------
The aims of this study were to analyze CD160 expression in both normal and pathological eyes from human adults to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease

Detailed Description
-----------------
Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and. CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.

Official Title
-----------------
CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

Conditions
-----------------
Surgical Retinal

Intervention / Treatment
-----------------
* Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks


Participation Criteria
=================
Eligibility Criteria
-----------------
inclusion criteria : Patients with retinal surgery Patients who agree to participate to the study Major patient exclusion criteria : Patient under law protection Minor patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| neovascular group<br>patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment | Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks<br> <br> |
| non-neovascular group<br>patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment. | Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CD160 staining intensity score | Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD160. The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD160 immunolabelling. | Day0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CD105 staining intensity score | Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD105. The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD105 immunolabelling. | Day0 |